Literature DB >> 12097259

Transactivation-deficient DeltaTA-p73 acts as an oncogene.

Thorsten Stiewe1, Sonja Zimmermann, Andreja Frilling, Helmut Esche, Brigitte M Pützer.   

Abstract

The recently discovered p53-family member p73 displays significant homology to p53, but data from primary tumors and knockout mice argue against p73 being a classical tumor suppressor. We report on the overexpression of NH(2)-terminally truncated, transactivation-deficient p73 proteins (DeltaTA-p73) in human cancer cells. Moreover, we show that DeltaTA-p73 overexpression results in malignant transformation of NIH3T3 fibroblasts and tumor growth in nude mice, thereby providing the experimental evidence for an oncogenic function of DeltaTA-p73. Apparently, increased expression of NH(2)-terminally truncated p73 isoforms conveys the TP73 gene with oncogenic activity that appears to be actively selected for during tumor development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097259

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells.

Authors:  A P Simões-Wüst; B Sigrist; L Belyanskaya; S Hopkins Donaldson; R A Stahel; U Zangemeister-Wittke
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

Review 2.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

3.  p73 poses a barrier to malignant transformation by limiting anchorage-independent growth.

Authors:  Michaela Beitzinger; Lars Hofmann; Claudia Oswald; Rasa Beinoraviciute-Kellner; Markus Sauer; Heidi Griesmann; Anne Catherine Bretz; Christof Burek; Andreas Rosenwald; Thorsten Stiewe
Journal:  EMBO J       Date:  2008-01-31       Impact factor: 11.598

Review 4.  Therapeutic prospects for p73 and p63: rising from the shadow of p53.

Authors:  Anna Vilgelm; Wael El-Rifai; Alexander Zaika
Journal:  Drug Resist Updat       Date:  2008-09-17       Impact factor: 18.500

Review 5.  Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences.

Authors:  Carmen Berasain; Saioa Goñi; Josefa Castillo; María Ujue Latasa; Jesús Prieto; Matías A Avila
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

6.  Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score.

Authors:  M Guan; Y Chen
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

7.  TAp73alpha protects small cell lung carcinoma cells from caspase-2 induced mitochondrial mediated apoptotic cell death.

Authors:  Naveen Muppani; Ulrika Nyman; Bertrand Joseph
Journal:  Oncotarget       Date:  2011-12

8.  Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.

Authors:  Stephan Emmrich; Weiwei Wang; Katja John; Wenzhong Li; Brigitte M Pützer
Journal:  Mol Cancer       Date:  2009-08-11       Impact factor: 27.401

9.  p73 is essential for vitamin D-mediated osteoblastic differentiation.

Authors:  R Kommagani; A Whitlatch; M K Leonard; M P Kadakia
Journal:  Cell Death Differ       Date:  2009-09-25       Impact factor: 15.828

10.  Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumours.

Authors:  Z Dong; Jc-S Pang; M H Ng; W S Poon; L Zhou; H-K Ng
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.